MedTrace Logo

Randomized Amifostine For SCCHN

NCT00095927 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2017-01-04

No results posted yet for this study

Summary

This research study is studying a drug called Amifostine as a treatment for squamous cell carcinoma in the head and/or neck area.

Conditions

Interventions

DRUG

Amifostine

Given subcutaneously

DRUG

Carboplatin

Given IV

DRUG

Paclitaxel

Given IV

RADIATION

radiation

Given once daily for 4 weeks and then twice daily for 2 weeks.

Sponsors & Collaborators

Principal Investigators

  • Robert I. Haddad, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2007-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00095927 on ClinicalTrials.gov